🧬 BioMed Pulse · 2026-06-15 04:55 UTC

BIOMED PULSE

June 15, 2026 | Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in DRC and Uganda has now reached 676 confirmed cases and 136 deaths as of June 10, making it the dominant global health emergency of 2026.

Mood is tense: a PHEIC is in force, airport screening is expanding, and a $518 million continental response plan just launched — while longevity science quietly advances on aging biomarkers and bone health.

🦠 OUTBREAKS & VIRUSES

EBOLA (BUNDIBUGYO VIRUS) — DRC AND UGANDA: ESCALATING PHEIC

• As of June 10, WHO reports 676 confirmed cases and 136 confirmed deaths in DRC from Bundibugyo virus disease (BVD), up from 515 confirmed cases on June 6.
• Cross-border transmission to Uganda is ongoing; the outbreak originated in Mongbwalu Health Zone, Ituri Province, DRC, first alerted May 5.
• WHO declared this outbreak a Public Health Emergency of International Concern (PHEIC) on May 17; it does not yet meet the criteria for pandemic emergency status.
• Africa CDC and WHO launched a joint continental preparedness and response plan on June 5, seeking to raise $518 million.
• WHO expert groups met May 28 to assess candidate vaccines and therapeutics specifically for Bundibugyo virus, a less-studied Ebola species than Zaire.
• ECDC assesses risk to the general European population as very low but is increasing on-the-ground support and urging EU/EEA countries to strengthen preparedness.
• CDC began enhanced Ebola airport screening at Washington-Dulles International Airport on May 21 and expanded it to Atlanta on May 23.

ANDES HANTAVIRUS — MV HONDIUS CRUISE SHIP, MULTI-COUNTRY

• This is the fourth WHO Disease Outbreak News update on the Andes hantavirus cluster first reported May 2 aboard M/V Hondius, a Dutch-flagged cruise ship carrying passengers and crew from 23 countries.
• As of the May 28 DON, additional confirmed cases were reported since the May 13 update; two confirmed cases were identified early, with five suspected cases initially, expanding over subsequent reports.
• ECDC confirmed the pathogen as Andes hantavirus, which uniquely among hantaviruses is capable of person-to-person transmission, distinguishing it from other hantavirus strains.
• 34 passengers and crew had previously disembarked before the cluster was identified, complicating contact tracing across multiple countries.

MPOX — GLOBAL: RECOMBINANT STRAIN AND EXPANDED CLADE Ib SPREAD

• WHO issued a February 14 DON on a recombinant MPXV strain carrying genomic elements of both clade Ib and clade IIb, with two cases documented; recombination occurs when two viral strains co-infect one host and exchange genetic material.
• A separate December 5 WHO DON flagged local clade Ib MPXV transmission among men who have sex with men in countries previously reporting only travel-linked cases, signaling broader geographic establishment.

NIPAH VIRUS — INDIA AND BANGLADESH

• India's National IHR Focal Point notified WHO on January 26 of two laboratory-confirmed Nipah virus cases in West Bengal, both healthcare workers at the same private hospital in Barasat, North 24 Parganas district.
• Bangladesh reported one confirmed Nipah case on February 3 in Rajshahi Division; the patient developed fever and neurological symptoms on January 21; NiV is confirmed by laboratory testing.
• Both events reflect the seasonal pattern of Nipah spillover in South Asia, associated with Pteropus fruit bat exposure.

MEASLES — BANGLADESH

• As of April 4, Bangladesh reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases spanning 58 of 64 districts across all eight divisions.
• The outbreak reflects widening gaps in measles vaccination coverage.

MERS-CoV — GLOBAL

• Since January 1 through December 21, 2025, WHO recorded 19 MERS-CoV cases including 4 deaths; 17 were reported by Saudi Arabia and 2 by France.
• ECDC's cumulative tally through June 1, 2026 stands at 2,649 total MERS cases and 960 deaths worldwide since April 2012.

AVIAN INFLUENZA

• The US reported its 71st confirmed human A(H5) case in November 2025, the first since February 2025, caused by influenza A(H5N5).
• Italy notified WHO on March 21, 2026 of a human A(H9N2) case in an adult male returning from Senegal, confirmed by next-generation sequencing.
• ECDC CDTRs for weeks 15 through 24 have continuously tracked avian influenza developments across EU/EEA.

BACTERIAL STIs — EUROPE

• ECDC data for 2024 show sexually transmitted infections at record highs in Europe, driven by sharp rises in gonorrhoea and syphilis.
• Congenital syphilis cases nearly doubled, indicating failures in antenatal screening and prevention reaching the most vulnerable.

LISTERIA — REQUESÓN AND SOFT RICOTTA CHEESE, US

• CDC is warning of an active Listeria monocytogenes outbreak linked to requesón and soft ricotta cheese; Nelson and Isa Lacteos LLC of Bayshore, NY recalled 1-lb packages of Requeson Cheese on June 5.
• Clover Hill Dairy of Mechanicsville, Maryland also recalled all Soft Ricotta/Requeson Cheese on June 9.
• Listeria poses the greatest risk to older adults, immunocompromised individuals, pregnant people, and newborns.

SALMONELLA — MORINGA CAPSULES, US

• CDC is tracking a growing number of Salmonella illnesses linked to moringa leaf supplement capsules.
• Total Nutrition Inc. of Deer Park, NY expanded its recall of TNVitamins and Doctor's Pride Ultra Potent Complete Green Superfood Moringa Capsules on June 11 following further supply chain review identifying additional implicated lots.

INFANT FORMULA — BOTULISM RISK

• CDC issued an outbreak update on June 13 warning parents to immediately stop using Nara Organics Whole Milk Organic Infant Formula due to potential Clostridium botulinum contamination.
• Nara Organics of New York, NY recalled all lots currently on the market; infant botulism is rare but potentially fatal.
• A separate WHO multi-country food safety event reported March 13 involves cereulide toxin contamination in infant formula and other products traced to a contaminated arachidonic acid oil ingredient used across multiple internationally distributed brands.

NEW WORLD SCREWWORM — US EMERGENCY RESPONSE

• CDC activated its Emergency Operations Center for a New World Screwworm response on June 12; this parasitic fly (Cochliomyia hominivorax) can infest living tissue and poses a zoonotic and human health risk.

🧬 LONGEVITY & AGING

DNA METHYLATION, TELOMERE LENGTH, AND INTRACRANIAL ANEURYSM RISK

• A genetic study published in IBRO Neuroscience Reports (Zhang X et al., Europe PMC PMID 42281947, May 30) used Mendelian randomization to examine whether DNA methylation-estimated biological age phenotypes and shorter telomere length causally increase risk of intracranial aneurysms.
• Telomere shortening is a well-established hallmark of cellular aging; this work links it to a serious vascular pathology affecting the brain.

INTRINSIC CAPACITY AND DISABILITY BEFORE DEATH

• A decedent cohort study by Malkowski OS, Davis-Plourde K, Western MJ, and Gill TM published in Lancet Healthy Longevity (PMID 42263724) examined how intrinsic capacity — the composite of all mental and physical capacities of an individual — relates to disability trajectories in the final period of life.
• Companion editorial by Hanewald K (PMID 42263725) in the same issue frames this as a dynamic relationship, suggesting intrinsic capacity is modifiable even near end of life.

ANTI-OSTEOPOROSIS MEDICATIONS AND FRACTURE HEALING

• A systematic review and meta-analysis by Agarwal N, Bell KR, Ross LE, Clement ND, Ralston SH, and Duckworth AD in Lancet Healthy Longevity (PMID 42229491) assessed whether anti-osteoporotic drugs (bisphosphonates, anabolic agents) affect fracture healing outcomes.
• Companion editorial by Paccou J (PMID 42229492) frames the clinical message as "treat the bone, not the fear," challenging longstanding hesitancy to prescribe these drugs around fracture events.

ALBUMIN AS AGING REDOX BIOMARKER

• Ishima Y et al. (Redox Reports, PMID 42228365, June 2) reviewed albumin's Cys34 residue as a dynamic biomarker of systemic oxidative stress, and described polysulfide-mediated homeostatic mechanisms that could be targets for aging-related interventions.
• Oxidized albumin fractions rise with age and in chronic disease, making Cys34 status a candidate blood-based aging clock component.

COLLAGEN OXIDATION AND TISSUE AGING

• Mathias-Netto FC, Cantuária NM, and Gaspar RS published in Redox Reports (PMID 42275020, June 11) on enzymatic and non-enzymatic oxidation of fibrillar collagen, a key extracellular matrix process driving tissue stiffening, skin aging, and organ fibrosis.

URIC ACID, FERROPTOSIS, AND NEURODEGENERATION

• Zhou D et al. (Redox Reports, PMID 42241031, June 4) showed uric acid alleviates inflammation in LPS-induced BV2 microglia and MPTP-induced Parkinson's disease mouse models by suppressing ferroptosis — a form of iron-dependent cell death — through activation of the Nrf2 signalling pathway.
• Ferroptosis is an emerging mechanism in age-related neurodegenerative diseases including Parkinson's and Alzheimer's.

PREBIOTICS, GUT MICROBIOME, AND PHYSICAL FUNCTION IN OBESITY AND OSTEOARTHRITIS

• Wang W, Fortuna R, Mayengbam S et al. in Gut Microbes (PMID 42231528, June 2) used multi-omics analysis to show prebiotic supplementation altered gut microbiota composition and metabolic pathways, with effects on physical function in adults with obesity and knee osteoarthritis — two age-accelerating conditions.

MATERNAL DIET, NEONATAL MICROBIOME, AND NEUROMETABOLIC RESILIENCE

• Kadyan S et al. in Gut Microbes (PMID 42262337, June 9) showed that maternal diet shapes neonatal microbiome ontogenesis and neurometabolic resilience, suggesting early-life microbiome programming has downstream effects on long-term health trajectories.

DELAYED CHILDBEARING AND REPRODUCTIVE AGING

• Yang D, Huang H, and He Y published a narrative review in the Journal of Obstetrics and Gynaecology (PMID 42261812, June 9) on how delayed childbearing intersects with ovarian aging biology, covering diminished ovarian reserve and implications for fertility and systemic aging.

DIGITAL DIVIDE AND HEALTH IN RURAL OLDER ADULTS — CHINA

• Ren W et al. in Global Health Action (PMID 42227082, June 2) found evidence from the CHARLS dataset that digital exclusion — lack of internet access and digital literacy — is associated with worse health status among rural older adults in China, adding a sociotechnical dimension to aging inequity.

💊 NEW CURES & APPROVALS

• VORANIGO (vorasidenib), sponsor Servier, NDA 218784 — supplemental approval action; vorasidenib is an IDH1/IDH2 inhibitor originally approved for diffuse glioma, a brain tumor predominantly affecting adults.
• RINVOQ LQ (upadacitinib), sponsor AbbVie, NDA 218347 — supplemental approval for a liquid formulation of this JAK1-selective inhibitor, which has indications spanning rheumatoid arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease.
• EBGLYSS (lebrikizumab-lbkz), sponsor Eli Lilly and Co, BLA 761306 — supplemental approval; lebrikizumab is an anti-IL-13 monoclonal antibody approved for moderate-to-severe atopic dermatitis.
• EXDENSUR (depemokimab-ulaa), sponsor GlaxoSmithKline LLC, BLA 761458 — supplemental approval; depemokimab is an ultra-long-acting anti-IL-5 monoclonal antibody targeting eosinophilic asthma and related conditions.
• TERLIVAZ (terlipressin acetate), sponsor Mallinckrodt Ireland, NDA 022231 — supplemental approval; terlipressin is a vasopressin analogue used for hepatorenal syndrome type 1, a life-threatening complication of advanced liver cirrhosis.
• MALARONE PEDIATRIC (atovaquone plus proguanil hydrochloride), sponsor GlaxoSmithKline, NDA 021078 — supplemental approval for this pediatric antimalarial combination.
• ARGATROBAN IN SODIUM CHLORIDE — two supplemental approvals, one for Cipla (NDA 022434) and one for Eugia Pharma Specialties (NDA 209552); argatroban is a direct thrombin inhibitor used in heparin-induced thrombocytopenia.
• PROPRANOLOL HYDROCHLORIDE — PAI Holdings received an original approval (ANDA 219165) for this established beta-blocker used in cardiac arrhythmias, hypertension, and tremor.
• VALACYCLOVIR HYDROCHLORIDE — Hetero Labs Ltd V received supplemental approval (ANDA 203047) for this antiviral prodrug of acyclovir used against herpes viruses including HSV and varicella-zoster.

🧪 CLINICAL TRIALS

HIV-ASSOCIATED ACCELERATED AGING AND ANTIRETROVIRAL METABOLIC EFFECTS

• NCT05652478 is a Phase 2 randomized study investigating the early metabolic effects — specifically weight gain and associated risks of diabetes and heart disease — of integrase strand transfer inhibitors (INSTIs) in healthy volunteers, addressing accelerated cardiometabolic aging in people living with HIV.
• NCT07621224, observing multimorbidity and polypharmacy in people with HIV versus the general population in the Basque Country, reflects the new reality that people with HIV now have life expectancy approaching that of the general population but accumulate age-related conditions faster.

COPD AND AIRWAY AGING — DUPILUMAB PHASE 4

• NCT07053423 is a multinational Phase 4 randomized double-blind trial studying dupilumab (anti-IL-4/IL-13 receptor) subcutaneously in participants aged 40 to 85 with COPD, assessing airway inflammation, resistance, remodeling, and mucus plugging — structural aging processes in lung tissue.

LUNG TRANSPLANT REJECTION — FOSTAMATINIB SYK INHIBITION (SIMILAR TRIAL)

• NCT06948097 (SIMILAR) evaluates fostamatinib, an oral Syk kinase inhibitor, for safety and tolerability in lung transplant recipients with donor-specific antibodies, aiming to prevent antibody-mediated rejection — a major driver of limited post-transplant survival currently averaging 6 to 7 years.

MEDICATION ADHERENCE IN OLDER ADULTS — ITACA APP

• NCT07631676 tests whether the Itaca mobile app versus usual care improves medication adherence in adults aged 65 and older on polypharmacy in a home care setting, addressing a major driver of adverse outcomes in aging populations.

KNEE OSTEOARTHRITIS — GENICULAR ARTERY EMBOLIZATION REGISTRY (RAMBO)

• NCT07380906 is a prospective real-world registry collecting long-term effectiveness and safety data on genicular artery embolization (GAE) as a minimally invasive alternative for adults with knee osteoarthritis that has not responded to medical therapy.

MANTLE CELL LYMPHOMA — IBRUTINIB PLUS RITUXIMAB IN OLDER PATIENTS

• NCT01880567 is a Phase 2 trial studying ibrutinib (BTK inhibitor) combined with rituximab (anti-CD20) for relapsed or refractory mantle cell lymphoma and for older, newly diagnosed patients — a population for whom aggressive chemotherapy carries higher risk.

PREHABILITATION FOR HIP AND KNEE ARTHROPLASTY

• NCT06721897 tests a structured prehabilitation exercise program before hip or knee arthroplasty surgery in an aging population with osteoarthritis, targeting faster functional recovery post-surgery.

COGNITIVE REMEDIATION IN ELDERLY DEPRESSION — VIRTUAL REALITY

• NCT07119008 investigates virtual reality as a tool for cognitive remediation in elderly depressed patients, targeting executive function impairment — a bidirectional link between late-life depression and dementia risk.

📢 PUBLIC HEALTH

EBOLA SCREENING AT US AIRPORTS

• Enhanced Ebola screening is active at Washington-Dulles International Airport (began May 21) and Hartsfield-Jackson Atlanta International Airport (began May 23), targeting travelers from DRC and Uganda.

NEW WORLD SCREWWORM — CDC EMERGENCY OPERATIONS CENTER ACTIVATED

• CDC activated its Emergency Operations Center on June 12 for a New World Screwworm (Cochliomyia hominivorax) response; this flesh-eating parasitic fly can infest open wounds in animals and, rarely, humans and has not been established in the US since eradication in the 1960s.

INFANT FORMULA SAFETY — BOTULISM AND CEREULIDE TOXIN

• Parents should immediately discard all Nara Organics Whole Milk Organic Infant Formula due to Clostridium botulinum contamination risk (CDC alert June 13).
• A separate multi-country WHO alert (March 13) covers cereulide toxin in multiple infant formula brands traced to contaminated arachidonic acid oil; affected products have been subject to international recalls.

FOOD RECALLS — LISTERIA AND SALMONELLA

• Active Listeria outbreak: requesón and soft ricotta cheese (Nelson and Isa Lacteos LLC; Clover Hill Dairy) — highest risk to elderly, immunocompromised, and pregnant individuals.
• Active Salmonella outbreak: TNVitamins and Doctor's Pride Moringa Capsules from Total Nutrition Inc. of Deer Park, NY — recall expanded June 11 following supply chain investigation.
• Additional recalls this week include Azuma Foods Tako Wasabi (undeclared fish allergen, 545 cases recalled, June 11) and Steve's Real Food Freeze-Dried Chicken Recipe by GO Raw LLC (low thiamine/vitamin B1 levels, June 8).

TRAVEL-RELATED COSMETIC PROCEDURES — CDC ADVISORY

• CDC issued a June 2 advisory highlighting adverse health outcomes linked to cosmetic procedures obtained abroad, urging travelers to verify facility accreditation and infection control standards before undergoing surgery or injections outside their home country.

WHO FOOD SAFETY ESTIMATE

• WHO released June 4 data estimating unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide; children under five face almost three times the illness risk of older children and adults.

BIOMED PULSE is informational only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health decisions.

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260615-04-v1 · 2026-06-15 04:55 UTC